RxDoctor Payments Data

Arnett Carraby, MD

Ophthalmology · Chula Vista, CANPI 1366530792

Payments from drug & device makers

$4,883in general payments, 2019–2025

Across 154 payments — averaging $31.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb Americas Inc.$468
  • Sun Pharmaceutical Industries Inc.$416
  • Dompe US, Inc.$311
  • AbbVie$279
  • Oyster Point Pharma, Inc.$265
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,883100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,883 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$566,122
Medicare patients
826
Services billed
2,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate1,110$34,099
XiidraLifitegrast25$23,887
Ketorolac Tromethamine1,049$15,089
Ofloxacin993$12,928
MieboPerfluorohexyloctane/Pf15$10,434
Cyclosporine17$8,292
LumiganBimatoprost16$6,097
Alphagan PBrimonidine Tartrate11$3,969
Brimonidine Tartrate41$2,344
Latanoprost147$1,377
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat39$693
Timolol Maleate14$164
ErythromycinErythromycin Base21$156
Potassium Chloride11$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$468$34,32140 claims
AbbVieLumigan, Alphagan P$279$10,06627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →